^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NKT2152

    i
    Other names: NKT2152, NKT-2152, NKT 2152, HS10516, HS-10516, HS 10516
    Associations

    News

    Trials
    Company:
    Jiangsu Hansoh Pharma, NiKang Therap
    Drug class:
    HIF-2α inhibitor
    Related drugs:
    Associations

    News

    Trials
    15d
    NKT2152-202: Ph2 Study NKT2152 with Palbociclib & Sasanlimab in Subjects with Advanced Clear Cell Renal Cell Carcinoma (ccRcc) (clinicaltrials.gov)
    P2, N=172, Active, not recruiting, NiKang Therapeutics, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Sep 2026 --> Jun 2026 | Trial primary completion date: Jun 2026 --> Jun 2025
    Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Ibrance (palbociclib) • sasanlimab (PF-06801591) • NKT2152
    30d
    NKT2152-101: A Study of NKT2152, a HIF2α Inhibitor, in Patients with Advanced Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
    P1/2, N=128, Active, not recruiting, NiKang Therapeutics, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2024 --> May 2025
    Enrollment closed • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    NKT2152
    3ms
    A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors (clinicaltrials.gov)
    P1, N=60, Recruiting, Jiangsu Hansoh Pharmaceutical Co., Ltd.
    New P1 trial
    |
    NKT2152
    6ms
    A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) (clinicaltrials.gov)
    P1/2, N=506, Recruiting, Hoffmann-La Roche | Trial completion date: Dec 2025 --> Aug 2026 | Trial primary completion date: Dec 2025 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • amezalpat (TPST-1120) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • NKT2152 • muzastotug (ADG126) • tobemstomig (RG6139)
    12ms
    A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
    P1/2, N=128, Recruiting, NiKang Therapeutics, Inc. | N=98 --> 128
    Enrollment change
    |
    PD-L1 (Programmed death ligand 1)
    |
    NKT2152
    over1year
    Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) (clinicaltrials.gov)
    P2, N=172, Not yet recruiting, NiKang Therapeutics, Inc.
    New P2 trial • Combination therapy • Metastases
    |
    Ibrance (palbociclib) • sasanlimab (PF-06801591) • NKT2152
    over1year
    A PHASE 1/2, OPEN LABEL DOSE-ESCALATION AND EXPANSION TRIAL OF NKT2152, AN ORALLY ADMINISTERED HIF2α INHIBITOR, TO INVESTIGATE SAFETY, PK, PD AND CLINICAL ACTIVITY IN PATIENTS WITH ADVANCED ccRCC (KCRS 2023)
    No abstract available
    Clinical • P1/2 data • Metastases
    |
    NKT2152
    2years
    A Phase 1/2, Open Label Dose- Escalation and Expansion Trial of NKT2152, an orally administered HIF2α inhibitor, to investigate safety. PK, PD and clinical activity in patients with advanced ccRCC (KCRS 2022)
    The study is currently actively accruing in the United States. Methods N/A Results N/A Conclusions N/A
    Clinical • P1/2 data
    |
    PD-L1 (Programmed death ligand 1) • VHL (von Hippel-Lindau tumor suppressor)
    |
    NKT2152
    3years
    A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
    P1/2, N=98, Recruiting, NiKang Therapeutics, Inc.
    New P1/2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    NKT2152